

September 2, 2021

VIA REGULATIONS.GOV

Division of Dockets Management
U.S. Food and Drug Administration
Department of Health and Human Services
Room 1061, HFA-305,
5630 Fishers Lane,
Rockville, MD 20852

RE: Withdrawal of Suitability Petition; Docket No. FDA-2020-P-1252

Dear Sir or Madam:

This Petitioner hereby requests withdrawal of the above-referenced citizen petition requesting that the Commissioner of Food and Drugs allow the submission of an ANDA for Lidocaine Hydrochloride Injection USP, 20mg /2mL (10mg/mL), 2 mL Fill vials (total vial content 20mg) pursuant to Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act and 21 CFR § 314.93.

Sincerely yours,



David L. Rosen, B.S. Pharm., JD

AUSTIN
BOSTON
CHICAGO
DALLAS
DENVER

DETROIT
HOUSTON
JACKSONVILLE
LOS ANGELES
MADISON

MEXICO CITY
MIAMI
MILWAUKEE
NEW YORK
ORLANDO

SACRAMENTO
SAN DIEGO
SAN FRANCISCO
SILICON VALLEY
TALLAHASSEE

TAMPA
WASHINGTON, D.C.
BRUSSELS
TOKYO